The effect of pharmacist intervention and patient education on lipid-lowering medication compliance and plasma cholesterol levels

Canadian Journal of Clinical Pharmacology

Volumn 10, Issue 3, 2003, Pages 101-106

  Ali, Farzad ^a   Laurin, Marie Yseult ^b   Larivière, Christine ^a   Tremblay, Denis ^a   Cloutier, Denise ^a  

^a PFIZER INC   (United States)

^b Pharmacy Benoit Favreau   (Canada)

Author keywords

Compliance; Disease management; Dyslipidemia; Lipid lowering therapy; Patient education; Pharmacists

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CONSULTATION; DYSLIPIDEMIA; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SATISFACTION; PHARMACIST; PRESCRIPTION; PROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; AGED; BLOOD; FEMALE; MALE; MIDDLE AGED; PILOT STUDY;

AGED; ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; CHOLESTEROL; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT EDUCATION; PHARMACISTS; PILOT PROJECTS; PRESCRIPTIONS, DRUG; PROSPECTIVE STUDIES;

EID: 0141904748     PISSN: 1198581X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. MacLean DR, Chockalingam A. The global burden of cardiovascular diseases. Can J Cardiol 1999;15(Suppl G):17G-9G.
2. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.
3. Ahmed SM, Clasen ME, Donnelly JE. Management of dyslipidemia in adults. Am Fam Physician 1998;57:2192-204.
4. Expert Panel on Detection, Evaluation, and Treatment of High Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
5. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
6. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
7. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.
8. Simes J, Furberg CD, Braunwald E, et al. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. Eur Heart J 2002;23:207-15.
9. American Heart Association. 2000 Heart and stroke statistical update. Dallas, Texas: 1999.
10. McKenney JM. The cost of treating dyslipidaemia using National Cholesterol Education Program (NCEP) guidelines. Pharmacoeconomics 1998;14(Suppl 3):19-28.
11. Fedder DO, Koro CE, L'Italien GJ. New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: Projected impact on the size, sex, and age distribution of the treatment-eligible population. Circulation 2002;105:152-6.
12. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 1996;164:208-11.
13. Insull W. The problem of compliance to cholesterol altering therapy. J Intern Med 1997;241:317-25.
14. Morrison A, Wertheimer AI. Evaluation of studies investigating the effectiveness of pharmacists' clinical services. Am J Health-Syst Pharm 2001;58:569-77.
15. Hawkins DW, Fiedler FP, Douglas HL, Eschbach RC. Evaluation of a clinical pharmacist in caring for hypertensive and diabetic patients. Am J Hosp Pharm 1979;36:1321-5.
16. Erickson SR, Slaughter R, Halapy H. Pharmacists' ability to influence outcomes of hypertension therapy. Pharmacotherapy 1997;17:140-7.
17. Coast-Senior EA, Kroner BA, Kelley CL, Trilli LE. Management of patients with type 2 diabetes by pharmacists in primary care clinics. Ann Pharmacother 1998;32:636-41.
18. Närhi U, Airaksinen M, Tanskanen M, Erlund H. Therapeutic outcomes monitoring by community pharmacists for improving clinical outcomes in asthma. J Clin Pharm Ther 2000;25:177-83.
19. Rupp MT, McCallian DJ, Sheth KK. Developing and marketing a community pharmacy-based asthma management program. J Am Pharm Assoc 1997;NS37:694-9.
20. Gattis WA, Hasselblad V, Whellan DJ, O'Connor CM. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: Results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. Arch Intern Med 1999;159:1939-45.
21. Diwan VK, Wahlstrom R, Tomson G, Beermann B, Sterky G, Eriksson B. Effects of "group detailing" on the prescribing of lipid-lowering drugs: a randomized controlled trial in Swedish primary care. J Clin Epidemiol 1995;48:705-11.
22. Bogden PE, Koontz LM, Williamson P, Abbott RD. The physician and pharmacist team. An effective approach to cholesterol reduction. J Gen Intern Med 1997;12:158-64.
23. Bozovich M, Rubino CM, Edmunds J. Effect of a clinical pharmacist-managed lipid clinic on achieving National Cholesterol Education Program low-density lipoprotein goals. Pharmacotherapy 2000;20:1375-83.
24. Furmaga EM. Pharmacist management of a hyperlipidemia clinic. Am J Hosp Pharm 1993;50:91-5.
25. Bluml BM, McKenney JM, Cziraky MJ. Pharmaceutical care services and results in project ImPACT: Hyperlipidemia. J Am Pharm Assoc 2000;40:157-65.
26. Ellis SL, Carter BL, Malone DC, et al. Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: the IMPROVE study. Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers. Pharmacotherapy 2000;20:1508-16.
27. Faulkner MA, Wadibia EC, Lucas BD, Hilleman DE. Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy 2000;20:410-6.
28. Tsuyuki RT, Johnson JA, Teo KK, et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: The Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med 2002;162:1149-55.
29. Gouvernement de Quebec, Regis de l'Assurance Maladie du Quebec, Manuel de pharmacien, Communication intéractives; mise à jour 23 décembre 1999:34.
30. Rogers EJ, Misner L, Ockene IS, Nicolosi RJ. Evaluation of seven Cholestech L.D.X analyzers for total cholesterol determinations. Clin Chem 1993;39:860-4.
31. Fodor JG, Frohlich JJ, Genest JJJ, McPherson PR. Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias. CMAJ 2000;162:1441-7.
32. LaRosa JH, LaRosa JC. Enhancing drug compliance in lipid-lowering treatment. Arch Fam Med 2000;9:1169-75.
33. National Cholesterol Education Program. Second report of the Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 1994;89:1333-445.
34. Rand CS. Measuring adherence with therapy for chronic diseases: implications for the treatment of heterozygous familial hypercholesterolemia. Am J Cardiol 1993;72:68D-74D.
35. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67.
36. Munroe WP, Kunz K, Dalmady-Israel C, Potter L, Schonfeld WH. Economic evaluation of pharmacist involvment in disease management in a community pharmacy setting. Clin Ther 1997;19:113-23.
37. Shibley MC, Pugh CB. Implementation of pharmaceutical care services for patients with hyperlipidemias by independent community pharmacy practitioners. Ann Pharmacother 1997;31:713-9.